Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Seock‐Ah Im, Alessandra Gennari, Y.H. Park, Jae Hyoung Kim, Zeping Jiang, Sameer Gupta, Trinugroho Heri Fadjari, Keita Tamura, M.Y. Mastura, Maria Luisa T. Abesamis-Tiambeng, Elaine Hsuen Lim, Ching‐Hung Lin, Aumkhae Sookprasert, Napa Parinyanitikul, Ling‐Ming Tseng, Sang‐Cheol Lee, Priscilla B. Caguioa, Maneesh Singh, Yoichi Naito, Ronald Hukom, BK Smruti, Shoei‐Shen Wang, S.B. Kim, Ki Hoon Lee, Hee Kyung Ahn, Solange Peters, T.W. Kim, Takayuki Yoshino, George Pentheroudakis, G. Curigliano, Nadia Harbeck
Abstract
•This article provides ESMO recommendations adapted for the treatment of MBC in Asian patients.•Evidence-based medicine and the availability to molecular diagnostic tests and treatments in Asian countries are discussed.•The aim is to encourage harmonisation of the management of MBC patients and to facilitate drug registration, across Asia. The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies. The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.